{"hq_id":"hq-p-wer-000088","name":"Hospital-Grade Disinfectant — Glutaraldehyde and OPA Occupational Exposure (Endoscope Reprocessing, Respiratory Sensitization, Anaphylaxis Risk with OPA)","category":{"primary":"workplace_hazard","secondary":"hospital_disinfectant","tags":["glutaraldehyde","OPA","ortho-phthalaldehyde","Cidex","hospital disinfectant","endoscope","reprocessing","occupational asthma","respiratory sensitization","anaphylaxis"]},"product_tier":"WER","overall_risk_level":"high","description":"Hospital-grade high-level disinfectants — glutaraldehyde (2.0-3.4%) and its successor ortho-phthalaldehyde (OPA, 0.55%) — are essential for reprocessing heat-sensitive semi-critical medical instruments, particularly flexible endoscopes used in over 18 million gastrointestinal, pulmonary, and urological procedures annually in the United States. While OPA was introduced as a less irritating alternative to glutaraldehyde (10-fold lower vapor pressure, no activation required, faster high-level disinfection at 12 minutes versus 45 minutes for GA), it has introduced its own unique hazard: IgE-mediated anaphylaxis in patients with repeated mucosal exposure to OPA-reprocessed instruments, particularly during cystoscopy (urological endoscopy) and laryngoscopy. The FDA issued a safety communication in 2004 and a Public Health Notification in 2006 regarding OPA-associated anaphylaxis, with over 100 reported cases including several fatalities. For healthcare workers, the occupational hazard profile of OPA includes skin staining (OPA irreversibly binds to skin proteins producing gray-black discoloration), contact sensitization, and emerging reports of occupational asthma similar to glutaraldehyde. The transition from glutaraldehyde to OPA has traded one set of occupational health risks for another, driving interest in non-aldehyde alternatives including peracetic acid automated systems and hydrogen peroxide gas plasma sterilization.","synthesis":{"derived_risk_level":"severe","synthesis_confidence":0.82,"synthesis_method":"compound_composition","context_used":"human_adult","context_source":"default","exposure_modifier":1,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-03-27","synthesis_version":"1.0.0"},"hazard_summary":{"sensitive_populations":"patients undergoing repeat endoscopy (especially cystoscopy — OPA anaphylaxis risk), sterile processing workers with daily aldehyde exposure, workers with pre-existing asthma or atopy, workers previously sensitized to formaldehyde (cross-reactivity with glutaraldehyde)","overall_risk":"high","primary_concerns":["Glutaraldehyde: occupational asthma in 2-8% of exposed workers — career-limiting sensitization","OPA: IgE-mediated anaphylaxis in patients with repeated mucosal exposure — >100 cases including fatalities","Both agents are skin and respiratory sensitizers — once sensitized, no safe exposure level exists","Transition from GA to OPA has traded occupational respiratory risk for patient anaphylaxis risk"],"exposure_routes":"Inhalation (glutaraldehyde vapor during manual reprocessing). Dermal (splash from both GA and OPA during instrument handling). Mucosal (patient exposure to residual OPA on incompletely rinsed instruments). Ocular (splash during pouring and decanting)."},"exposure":{"routes":["inhalation","dermal","ocular","mucosal"],"contact_types":["inhalation_vapor","dermal_splash","ocular_splash","mucosal_patient_exposure"],"users":["endoscopy_technician","sterile_processing_worker","nurse","patient"],"duration":"chronic","frequency":"daily_occupational","scenarios":["Sterile processing worker manually reprocesses 15-20 endoscopes per shift using glutaraldehyde — cumulative vapor inhalation exceeding OSHA ceiling","Endoscopy technician switches to OPA — develops skin staining on hands and forearms from repeated splash exposure despite glove use","Patient undergoing repeat cystoscopy with OPA-reprocessed cystoscope develops intraoperative anaphylaxis requiring epinephrine and ICU admission","Automated endoscope reprocessor (AER) malfunction: glutaraldehyde or OPA spill during drain cycle — acute high-concentration vapor exposure in enclosed reprocessing room"],"notes":"Glutaraldehyde: see phase 60 entry for detailed occupational profile. OPA (ortho-phthalaldehyde): CAS 643-79-8; 0.55% solution (Cidex OPA, Johnson & Johnson). Vapor pressure: 0.04 mmHg at 20C (10x lower than GA). HLD time: 12 min at 20C (vs GA 45 min). Patient anaphylaxis: IgE against OPA-modified proteins; >100 reported cases; FDA PHN 2006. Risk factor: repeat mucosal exposure (cystoscopy patients). Mechanism: OPA reacts with lysine residues on instrument surface proteins → neoantigen → IgE sensitization → anaphylaxis on re-exposure. Worker effects: skin staining (gray-black, irreversible protein binding), emerging occupational asthma reports, contact dermatitis. Peracetic acid (PAA): non-aldehyde alternative — no respiratory sensitization, no patient anaphylaxis, fully automated (Steris System 1E)."},"consumer_guidance":{"usage_warning":"Healthcare facilities should implement exposure monitoring for glutaraldehyde (target: below ACGIH TLV-C 0.05 ppm) and transition to automated endoscope reprocessors to reduce worker exposure. If using OPA: implement extended rinsing protocols (minimum 3 rinse cycles) for instruments used in repeat mucosal procedures (cystoscopy, laryngoscopy) to minimize patient anaphylaxis risk. Screen patients for prior OPA-reprocessed instrument exposure before repeat endoscopy. Report all suspected OPA anaphylaxis events to FDA MedWatch.","safer_alternatives":["Peracetic acid automated systems (Steris System 1E) — no respiratory sensitization, no patient anaphylaxis, fully enclosed","Hydrogen peroxide gas plasma sterilization (Sterrad) for compatible instruments","Electrolyzed water (hypochlorous acid) — emerging alternative for some instruments","Single-use disposable endoscope components reducing reprocessing requirement"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Public Health Notification on OPA Anaphylaxis and OSHA Aldehyde Exposure Limits","citation":"FDA Public Health Notification: Reprocessing Endoscopes (2006); OSHA Glutaraldehyde Ceiling 0.2 ppm; ACGIH TLV-C 0.05 ppm for GA","requirements":"FDA issued Public Health Notification (2006) regarding anaphylaxis associated with OPA-reprocessed medical instruments, particularly in patients with repeated bladder exposure. OSHA glutaraldehyde ceiling: 0.2 ppm (not to be exceeded). ACGIH TLV-C: 0.05 ppm. No specific OSHA PEL for OPA. FDA mandates validated reprocessing protocols for all endoscope HLD agents. CMS surveys for endoscope reprocessing compliance under Conditions of Participation.","compliance_status":null,"effective_date":"2006-10-01","enforcing_agency":"FDA CDRH / OSHA / CMS","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Spent glutaraldehyde: neutralize with glycine or sodium bisulfite before drain disposal per local POTW limits. Spent OPA: check local disposal regulations — OPA is more resistant to neutralization than glutaraldehyde.","hazardous_waste":true,"expected_lifespan":"Glutaraldehyde activated solutions: 14-28 day reuse life. OPA: 14-day reuse life or per MEC strip testing."},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000011","compound_name":null,"role":"aldehyde_class","typical_concentration":"glutaraldehyde 2.0-3.4%; OPA 0.55%; both are respiratory and skin sensitizers; OPA causes anaphylaxis in repeatedly exposed patients"}],"identifiers":{"common_names":["hospital-grade disinfectant — glutaraldehyde and opa occupational exposure (endoscope reprocessing, respiratory sensitization, anaphylaxis risk with opa)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-01T14:27:17.441Z"}}